ACRX AcelRx Pharmaceuticals Inc.
2.42
+0.01 (+1%)
Previous Close
2.41
Open
2.42
Price To Book
-24.23
Market Cap
191,216,925
Shares
78,914,170
Volume
16,475
Short Ratio
Av. Daily Volume
1,465,344
NewsSee all news
- Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
- Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT
- AcelRx announces the closing of a $25 million senior secured debt facility
- AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
- AcelRx Pharmaceuticals Inc (ACRX) Q1 2019 Earnings Call Transcript
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
DSUVIA (ARX-04)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery
Latest News
- Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
- Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT
- AcelRx announces the closing of a $25 million senior secured debt facility
- AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
- AcelRx Pharmaceuticals Inc (ACRX) Q1 2019 Earnings Call Transcript
- Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today
- AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
- AcelRx Pharmaceuticals: 1Q Earnings Snapshot
- AcelRx Pharmaceuticals, Inc. to Host Earnings Call
- What's in the Cards for AcelRx (ACRX) This Earnings Season?
- Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know
- 3 Stocks Peter Lynch Would Love
- AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019
- AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting
- Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT
- Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
- AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?
- AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference
- Why AcelRx Pharmaceuticals Stock Is Sinking Today